Publication . Ferreira, Tiago Bruno Pereira Soares; Alves, Paula Marques; Carrondo, Manuel José Teixeira
"Adenovirus vectors (AdV) have attracted considerable interest over the
past decade, with ongoing clinical development programs for applications
ranging from replacement therapy for protein deficiencies to cancer
therapeutics to prophylactic vaccines. In fact, in the period 1989-2005,
over 300 clinical trials were conducted using adenoviruses worldwide,
adenovirus type 5 (Ad5) being the vector of choice. Consequently,
considerable product process, analytical and formulation development has
to be carried out in order to respond to the constantly increasing market
requirements for AdV.(...)"